Forskning
Udskriv Udskriv
Switch language
Rigshospitalet - en del af Københavns Universitetshospital
E-pub ahead of print

Days alive and out of hospital after enhanced recovery video-assisted thoracoscopic surgery lobectomy

Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

DOI

  1. Reintervention rates following bioprosthetic surgical aortic valve replacement-a Danish Nationwide Cohort Study

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  2. Sympathovagal imbalance decades after atrial septal defect repair: a long-term follow-up study

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  3. Is complex segmentectomy safe?

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  4. The Fontan operation: when and why?

    Publikation: Bidrag til tidsskriftLederForskningpeer review

  1. Reasons for staying in hospital after video-assisted thoracoscopic surgery lobectomy

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  2. AHA STEROID trial, dexamethasone in acute high-risk abdominal surgery, the protocol for a randomized controlled trial

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  3. Functional recovery after discharge in enhanced recovery video-assisted thoracoscopic lobectomy: a pilot prospective cohort study

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  4. Radical Minimally Invasive Surgery After Immuno-chemotherapy in Initially-unresectable Stage IIIB Non-small cell Lung Cancer

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

Vis graf over relationer

OBJECTIVES: Days alive and out of hospital (DAOH) integrates overall information of hospitalization, readmissions, and mortality that have been applied as a new outcome measure. However, DAOH after video-assisted thoracoscopic surgery (VATS) in an established enhanced recovery after surgery (ERAS) programme has not been reported.

METHODS: Patients aged ≥18 years with non-small-cell lung cancer undergoing VATS lobectomy in an established ERAS programme were eligible. The primary and secondary outcomes were DAOH during the first postoperative 365 days and reasons for reduced DAOH.

RESULTS: A total of 316 consecutive patients with well-defined inclusion criteria and complete follow-up were assessed retrospectively. The median length of stay was 3 days (IQR 2-6). The medians (IQR) of postoperative 30, 60, 90, 180 and 365 DAOH were 27 (22-28), 57 (51-58), 86 (80-88), 176 (169-178) and 359 (349-363) days, respectively. Air leak was the dominant factor for reduced DAOH from postoperative day (POD) 0-30 (47.2%) and 0-365 (38.3%). Side effects of adjuvant chemotherapy were dominant from POD 31-60 and 61-90 (23.5% and 47.1%) and recurrence/metastases from POD 91-180 and 181-365 (25.6% and 50.0%). A low diffusing capacity for carbon monoxide (odds ratios 1.28, 95% confidence interval 1.07-1.53; P=0.007) and prior surgical history (odds ratios 1.80, 95% confidence interval 1.08-2.99; P=0.023) were predictors for low DAOH.

CONCLUSIONS: DAOH after 1 year with an established VATS lobectomy ERAS programme was only reduced with a median of 6 days. The main factors reducing DAOH were air leak, adjuvant chemotherapy and recurrence. DAOH may be an important patient-centred outcome to define future improvement strategies.

OriginalsprogEngelsk
Artikelnummerezac148
TidsskriftEuropean journal of cardio-thoracic surgery : official journal of the European Association for Cardio-thoracic Surgery
ISSN1010-7940
DOI
StatusE-pub ahead of print - 2022

Bibliografisk note

© The Author(s) 2022. Published by Oxford University Press on behalf of the European Association for Cardio-Thoracic Surgery. All rights reserved.

ID: 75350275